Raptor Announces NIDDK Provides Additional Data From CyNCh Study Evaluating RP103 in Pediatric NASH at AASLD

Raptor Pharmaceutical Corp.

today announced researchers have provided additional results from the CyNCh study of RP103 for the treatment of children 8 to 17 years with biopsy-confirmed moderate-to-severe nonalcoholic fatty liver disease, or NAFLD. The data will be presented today at the American Association for the Study of Liver Diseases (AASLD) Annual Meeting (The Liver Meeting®) at the Moscone Center in San Francisco in a late-breaking poster (#LB-31) entitled "Cysteamine Bitartrate Delayed-Release (DR) for the Treatment of Nonalcoholic Fatty Liver Disease (NAFLD) in Children (CyNCh Trial)." Joel Lavine, M.D., Ph.D. will discuss the data at a CME Symposium entitled "An Urgent Update on Pediatric Nonalcoholic Steatohepatitis (NASH): Management of Pediatric NASH: Current and Emerging Approaches" at 7:40 p.m. PT at the Marriott Marquis, Yerba Buena Salon 9 in San Francisco. As previously reported by the company on September 14, 2015, an evaluation of the primary endpoint of change in baseline liver histology as measured by a NAS score decrease of ≥2 and no worsening of fibrosis, there was no difference in the response rate between RP103 and placebo (28% versus 22%, respectively; p=0.34). Based upon additional analyses of the CyNCh study conducted by NIDDK